The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Six‐month results of a double‐blind, placebo‐controlled trial of etanercept treatment in patients with active ankylosing spondylitis
Abstract
Objective: There is increasing evidence that tumor necrosis factor α (TNFα) is centrally involved in the pathogenesis of ankylosing spondylitis (AS) and other spondylarthritides. This study was designed to investigate the efficacy of anti‐TNFα therapy with etanercept, a 75‐kd receptor fusion protein, in active AS. Methods: This multicenter trial had 2 phases: an initial placebo‐controlled period of 6 weeks' duration and an observational phase lasting 24 weeks. Thirty patients with active AS were included. They were randomized into 2 groups, which received either etanercept (25 mg twice weekly) (n = 14) or placebo (n = 16) for 6 weeks. Then both groups were treated with etanercept. Nonsteroidal antiinflammatory drug (NSAID) treatment could be continued, but disease‐modifying antirheumatic drugs (DMARDs) and steroids had to be withdrawn prior to the study. All patients received etanercept for a total of 12 weeks and were followed up for at least 24 weeks. The Bath AS Disease Activity Index (BASDAI), Bath AS Functional Index, Bath AS Metrology Index, pain level on a numeric rating scale, quality of life by the Short Form 36, and C‐reactive protein (CRP) level were assessed. The primary outcome parameter was a ≥50% improvement in the BASDAI. Results: Treatment with etanercept resulted in at least a 50% regression of disease activity in 57% of these patients at week 6, versus 6% of the placebo‐treated patients ( P = 0.004). After the placebo‐treated patients switched to etanercept, 56% improved. The mean ± SD BASDAI improved from 6.5 ± 1.2 at baseline to 3.5 ± 1.9 at week 6 in the etanercept group, with no improvement in the placebo group ( P = 0.003 between groups). Similarly, pain, function, mobility, and quality of life improved with etanercept but not with placebo at week 6 ( P < 0.05). Mean CRP levels decreased significantly with etanercept but not with placebo ( P = 0.001). There was ongoing improvement in all parameters in both groups until week 12 and week 18, respectively (i.e., throughout the period of etanercept treatment). Disease relapses occurred a mean ± SD of 6.2 ± 3.0 weeks after cessation of etanercept. No severe adverse events, including major infections, were observed during the trial. Conclusion: This study shows that on a short‐term basis (3 months), treatment with etanercept is clearly efficacious in patients with active AS who are receiving NSAID therapy but not DMARDs or steroids. After cessation of therapy, almost all patients experienced a relapse within a few weeks. Thus, it seems probable that etanercept must be administered continuously in most AS patients to achieve permanent inhibition of the inflammatory process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
Evaluation of Diagnostic Criteria for Ankylosing Spondylitis
Linden, S. V. D., Valkenburg, H. A., & Cats, A. (1984) · Arthritis & Rheumatism · doi:10.1002/art.1780270401 · Cited by 5,697
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
Keane, J., Gershon, S., Wise, R. P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W. D., Siegel, J. N., & Braun, M. M. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011110 · Cited by 3,710
Garrett, S., Jenkinson, T., Kennedy, L. G., Whitelock, H., Gaisford, P., & Călin, A. (1994) · PubMed · Cited by 3,241
Călin, A., Garrett, S., Whitelock, H., Kennedy, L. G., O'Hea, J., MALLORIE, P. A., & Jenkinson, T. (1994) · PubMed · Cited by 1,834
(2001) · Classic Papers in Rheumatology · doi:10.3109/9780203214237-70 · Cited by 1,833
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
Mease, P. J., Goffe, B. S., Metz, J., VanderStoep, A., Finck, B., & Burge, D. J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02530-7 · Cited by 1,446
Etanercept Therapy in Rheumatoid Arthritis: A Randomized, Controlled Trial
Moreland, L. W., Schiff, M. H., Baumgartner, S. W., Tindall, E. A., Fleischmann, R. M., Bulpitt, K. J., Weaver, A. L., Keystone, E. C., Furst, D. E., Mease, P. J., et al. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00004 · Cited by 1,379
Braun, J., Brandt, J., Listing, J., Zink, A., Alten, R., Golder, W., Gromnica-lhle, E., Kellner, H., Krause, A., Schneider, M., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08215-6 · Cited by 1,261
Self-citationDefining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index.
Jenkinson, T., MALLORIE, P. A., Whitelock, H., KENNEDY, L. G., Garrett, S. L., & Călin, A. (1994) · PubMed · Cited by 981
Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors
Braun, J., Bollow, M., Remlinger, G., Eggens, U., Rudwaleit, M., Distler, A., & Sieper, J. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199801)41:1<58::aid-art8>3.0.co;2-g · Cited by 933
Self-citationEtanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
Sandborn, W. J., Hanauer, S. B., Katz, S., Safdi, M., Wolf, D. G., Baerg, R. D., Tremaine, W. J., Johnson, T., Diehl, N. N., & Zinsmeister, A. R. (2001) · Gastroenterology · doi:10.1053/gast.2001.28674 · Cited by 910
Treatment of Ankylosing Spondylitis by Inhibition of Tumor Necrosis Factor α
Gorman, J. D., Sack, K. E., & Davis, J. C. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012664 · Cited by 704
Braun, J., Bollow, M., Neure, L., Seipelt, E., Seyrekbasan, F., Herbst, H., Eggens, U., Distler, A., & Sieper, J. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380407 · Cited by 690
Self-citationAnderson, J. J., Baron, G., Van Der Heijde, D., Felson, D. T., & Dougados, M. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200108)44:8<1876::aid-art326>3.0.co;2-f · Cited by 606
Brandt, J., Haibel, H., Cornely, D., Golder, W., Gonzalez, J., Reddig, J., Thriene, W., Sieper, J., & Braun, J. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200006)43:6<1346::aid-anr18>3.0.co;2-e · Cited by 485
Self-citationTREATMENT OF ANKYLOSING SPONDYLITIS BY INHIBITION OF TUMOR NECROSIS FACTOR a
Orman, D., Enneth, K., Ack, E. S., Ohn, J., & Avis, C. D. (2002) · Cited by 470
Lee, J., Slifman, N. R., Gershon, S. K., Edwards, E. T., Schwieterman, W. D., Siegel, J. N., Wise, R. P., Brown, S. L., Udall, J. N., & Braun, M. M. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10583 · Cited by 443
Braun, J., Baraliakos, X., Golder, W., Brandt, J., Rudwaleit, M., Listing, J., Bollow, M., Sieper, J., & van der Heijde, D. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10883 · Cited by 397
Self-citationZink, A., Braun, J., Listing, J., & Wollenhaupt, J. (2000) · PubMed · Cited by 319
Self-citationvan der Heijde, D. M. F. M., Bellamy, N., Călin, A., Dougados, M., Ma, K., & van der Linden, S. (1997) · PubMed · Cited by 240
Gran, J. T., Husby, G., & Hordvik, M. (1985) · Annals of the Rheumatic Diseases · doi:10.1136/ard.44.6.359 · Cited by 235
Ileocolonoscopic Findings in Seronegative Spondylarthropathies
Mielants, H., Veys, E. M., Cuvelier, C., & de Vos, M. (1988) · Rheumatology · doi:10.1093/rheumatology/xxvii.suppl_2.95 · Cited by 184
Pathogenesis of spondylarthropathies
Sieper, J., & Braun, J. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780381105 · Cited by 156
Self-citationPROGNOSIS, COURSE OF DISEASE, AND TREATMENT OF THE SPONDYLOARTHROPATHIES
Leirisalo‐Repo, M. (1998) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(05)70039-9 · Cited by 143
Zink, A., Listing, J., Klindworth, C., & Zeidler, H. (2001) · Annals of the Rheumatic Diseases · doi:10.1136/ard.60.3.199 · Cited by 131
Self-citationBraun, J., & Sieper, J. (2002) · Arthritis Research · doi:10.1186/ar592 · Cited by 124
Self-citationEfficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis
Marzo‐Ortega, H., McGonagle, D., O'Connor, P., & Emery, P. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.62.1.74 · Cited by 108
Course of gut inflammation in spondylarthropathies and therapeutic consequences
Mielants, H., VEYS, E. M., Cuvelier, C. A., & Vos, M. D. (1996) · Baillière s Clinical Rheumatology · doi:10.1016/s0950-3579(96)80010-0 · Cited by 101
Is methotrexate effective in ankylosing spondylitis?
Roychowdhury, B. (2002) · British journal of rheumatology · doi:10.1093/rheumatology/41.11.1330 · Cited by 89
Employment perspectives of patients with ankylosing spondylitis
Chorus, A. M. J., Boonen, A., Miedema, H. S., et al. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.8.693 · Cited by 83
Drug-induced systemic lupus erythematosus and TNF-α blockers
MOHAN, A. K., Edwards, E. T., Coté, T. R., Siegel, J. N., & Braun, M. M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09800-8 · Cited by 82
Treatment of ankylosing spondylitis with disease modifying antirheumatic drugs.
van der Horst-Bruinsma, I. E., Clegg, D. O., & Dijkmans, B. A. C. (2002) · PubMed · Cited by 37
Komuro (2001) · doi:10.1002/1529-0131(200112)44:12
Cited by
Adverse effects of biologics: a network meta-analysis and Cochrane overview
Singh, J. A., Wells, G. A., Christensen, R., Tanjong Ghogomu, E., Maxwell, L. J., MacDonald, J. K., Filippini, G., Skoetz, N., Francis, D. K., Lopes, L. C., et al. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008794.pub2 · Cited by 823
ASAS/EULAR recommendations for the management of ankylosing spondylitis
Zochling, J., van der Heijde, D., Burgos-Vargas, R., Collantes, E., Davis, J. C., Dijkmans, B., Dougados, M., Géher, P., Inman, R. D., Khan, M. A., et al. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.041137 · Cited by 702
Self-citationUpdated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Self-citationRudwaleit, M., Khan, M. A., & Sieper, J. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20990 · Cited by 515
Self-citationRudwaleit, M., Listing, J., Brandt, J., Braun, J., & Sieper, J. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.016386 · Cited by 439
Self-citation
Metadata
- Authors
- Brandt, J., Khariouzov, A., Listing, J., Haibel, H., Sörensen, H., Grassnickel, L., Rudwaleit, M., Sieper, J., & Braun, J.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2003-06
- Volume
- 48
- Issue
- 6
- Pages
- 1667-1675
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W1995356102
- Cited by
- 458
- References
- 35
- FWCI
- 25.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.